Malaria remains a significant global health issue, especially in tropical and subtropical regions. Although Egypt attained malaria-free status in 2024, countries like Eritrea, Ethiopia, Ghana, Kenya, Nigeria, Somalia, Sri Lanka, Sudan, and Yemen are still considered "High Burden High Impact" zones. Malaria causes over 435,000 fatalities annually and places billions more at risk. Unfortunately, treatment resistance, atypical symptomology, analytical sensitivity, and the specificity of conventional detection methods have made diagnosis challenging. To mitigate the large reservoir of malaria parasites in disease hotspots, a more strategic non-invasive diagnostic tool with improved monitoring, multiplex capability and analytical performance is required. Fortunately, the advent of novel biosensor technology that uses advanced nanotechnology design and biochemical approaches provides rapid, sensitive, and cost-effective alternatives. Furthermore, these user-friendly devices require minimal technical expertise and are ideal at the point of care, especially in remote and resource-limited settings. Herein, we examine current and emerging diagnostic tools and evaluate their potential to revolutionize malaria control and eradication efforts worldwide.
{"title":"Advances in malaria detection.","authors":"Blessing Wisdom Ike, Vijayaraj Kathiresan, Lungelo Miya, Rajshekhar Karpoormath","doi":"10.1016/bs.acc.2025.06.004","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.06.004","url":null,"abstract":"<p><p>Malaria remains a significant global health issue, especially in tropical and subtropical regions. Although Egypt attained malaria-free status in 2024, countries like Eritrea, Ethiopia, Ghana, Kenya, Nigeria, Somalia, Sri Lanka, Sudan, and Yemen are still considered \"High Burden High Impact\" zones. Malaria causes over 435,000 fatalities annually and places billions more at risk. Unfortunately, treatment resistance, atypical symptomology, analytical sensitivity, and the specificity of conventional detection methods have made diagnosis challenging. To mitigate the large reservoir of malaria parasites in disease hotspots, a more strategic non-invasive diagnostic tool with improved monitoring, multiplex capability and analytical performance is required. Fortunately, the advent of novel biosensor technology that uses advanced nanotechnology design and biochemical approaches provides rapid, sensitive, and cost-effective alternatives. Furthermore, these user-friendly devices require minimal technical expertise and are ideal at the point of care, especially in remote and resource-limited settings. Herein, we examine current and emerging diagnostic tools and evaluate their potential to revolutionize malaria control and eradication efforts worldwide.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"155-180"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/S0065-2423(25)00076-9
Gregory S Makowski
{"title":"Preface.","authors":"Gregory S Makowski","doi":"10.1016/S0065-2423(25)00076-9","DOIUrl":"https://doi.org/10.1016/S0065-2423(25)00076-9","url":null,"abstract":"","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"xv-xvi"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-01-09DOI: 10.1016/bs.acc.2024.11.008
Kevin Roe
Organisms as well as pathogens require several transition metals including iron, copper, zinc, manganese, nickel and cobalt, for genetic replication and other cellular functions. Of these, iron is vital and plays a key role in DNA replication, transcription, synthesis of cofactors and other essential enzymes. During infection, iron deprivation, particularly sequestration thereof, represents a unique response against pathogen attack. The host sequesters ferrous (Fe2+) and ferric (Fe3+) iron via lactoferrin binding at mucosal surfaces, transferrin in blood and tissue and ferritin in blood and cytoplasm. Despite this protective mechanism, pathogens can be resilient in obtaining iron. For example, hemolytic protozoan parasites can obtain iron from heme by rupturing red blood cells. Furthermore, earlier pathogens, driven from active to inactive infections by iron deprivation, could now acquire sufficient iron to enable reactivation resulting in chronic inflammation, oxidative stress to organs and/or circulatory hypertension potentially leading to death. This review discusses the impact of hemolytic protozoan parasite infection in reactivation of latent iron-deprived pathogen infections thus explaining two puzzling pregnancy disorders, pre-eclampsia (PE) and eclampsia. The unknown causations of both disorders have created centuries of confusion and killed millions of women worldwide. Furthermore, reduction-oxidation reactions with iron promote additional oxidative stress damage to vital organs, particularly the kidneys, a common symptom in PE and eclampsia.
{"title":"Preeclampsia and eclampsia: the role of hemolytic protozoan iron.","authors":"Kevin Roe","doi":"10.1016/bs.acc.2024.11.008","DOIUrl":"10.1016/bs.acc.2024.11.008","url":null,"abstract":"<p><p>Organisms as well as pathogens require several transition metals including iron, copper, zinc, manganese, nickel and cobalt, for genetic replication and other cellular functions. Of these, iron is vital and plays a key role in DNA replication, transcription, synthesis of cofactors and other essential enzymes. During infection, iron deprivation, particularly sequestration thereof, represents a unique response against pathogen attack. The host sequesters ferrous (Fe<sup>2+</sup>) and ferric (Fe<sup>3+</sup>) iron via lactoferrin binding at mucosal surfaces, transferrin in blood and tissue and ferritin in blood and cytoplasm. Despite this protective mechanism, pathogens can be resilient in obtaining iron. For example, hemolytic protozoan parasites can obtain iron from heme by rupturing red blood cells. Furthermore, earlier pathogens, driven from active to inactive infections by iron deprivation, could now acquire sufficient iron to enable reactivation resulting in chronic inflammation, oxidative stress to organs and/or circulatory hypertension potentially leading to death. This review discusses the impact of hemolytic protozoan parasite infection in reactivation of latent iron-deprived pathogen infections thus explaining two puzzling pregnancy disorders, pre-eclampsia (PE) and eclampsia. The unknown causations of both disorders have created centuries of confusion and killed millions of women worldwide. Furthermore, reduction-oxidation reactions with iron promote additional oxidative stress damage to vital organs, particularly the kidneys, a common symptom in PE and eclampsia.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"125 ","pages":"169-194"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/S0065-2423(25)00008-3
Gregory S Makowski
{"title":"Preface.","authors":"Gregory S Makowski","doi":"10.1016/S0065-2423(25)00008-3","DOIUrl":"https://doi.org/10.1016/S0065-2423(25)00008-3","url":null,"abstract":"","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"124 ","pages":"xiii-xiv"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-03-15DOI: 10.1016/bs.acc.2025.01.004
Hafiz Muhammad Arsalan, Hina Mumtaz, Antonio Simone Lagana
Endometriosis represents a diverse disease characterized by three distinct phenotypes: superficial peritoneal lesions, ovarian endometriomas, and deep infiltrating endometriosis. The most widely accepted pathophysiological hypothesis for endometriosis is rooted in retrograde menstruation, a phenomenon observed in most patients. Endometriosis is closely linked to infertility, but having endometriosis does not necessarily imply infertility. The disease can impact fertility through various mechanisms affecting the pelvic cavity, ovaries, and the uterus itself. MicroRNAs (miRNAs) indeed represent a fascinating and essential component of the regulatory machinery within cells. Discovered in the early 1990s, miRNAs have since been identified as critical players in gene expression control. Unfortunately, ovarian endometrioma is a common gynecologic disorder for which specific serum markers are currently lacking. Some have examined urocortin for its ability to differentiate endometriomas from other benign ovarian cysts. Another potential marker, Cancer Antigen 125 (CA-125) is a well-established indicator for epithelial cell ovarian cancer and its levels can be elevated in conditions such as endometriosis. CA-125 is derived from coelomic epithelia, including the endometrium, fallopian tube, ovary, and peritoneum. In this review we examine the pathophysiologic basis for endometriosis and highlight potential markers to more fully characterize the underlying biochemical processes linked to this multifaceted disease state.
{"title":"Biomarkers of endometriosis.","authors":"Hafiz Muhammad Arsalan, Hina Mumtaz, Antonio Simone Lagana","doi":"10.1016/bs.acc.2025.01.004","DOIUrl":"10.1016/bs.acc.2025.01.004","url":null,"abstract":"<p><p>Endometriosis represents a diverse disease characterized by three distinct phenotypes: superficial peritoneal lesions, ovarian endometriomas, and deep infiltrating endometriosis. The most widely accepted pathophysiological hypothesis for endometriosis is rooted in retrograde menstruation, a phenomenon observed in most patients. Endometriosis is closely linked to infertility, but having endometriosis does not necessarily imply infertility. The disease can impact fertility through various mechanisms affecting the pelvic cavity, ovaries, and the uterus itself. MicroRNAs (miRNAs) indeed represent a fascinating and essential component of the regulatory machinery within cells. Discovered in the early 1990s, miRNAs have since been identified as critical players in gene expression control. Unfortunately, ovarian endometrioma is a common gynecologic disorder for which specific serum markers are currently lacking. Some have examined urocortin for its ability to differentiate endometriomas from other benign ovarian cysts. Another potential marker, Cancer Antigen 125 (CA-125) is a well-established indicator for epithelial cell ovarian cancer and its levels can be elevated in conditions such as endometriosis. CA-125 is derived from coelomic epithelia, including the endometrium, fallopian tube, ovary, and peritoneum. In this review we examine the pathophysiologic basis for endometriosis and highlight potential markers to more fully characterize the underlying biochemical processes linked to this multifaceted disease state.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"126 ","pages":"73-120"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Metabolic syndrome is a group of cardio-metabolic dysfunctions characterized by increased fasting blood glucose, blood pressure, waist circumference, triglycerides, and decreased high-density lipoprotein cholesterol. Globally, the prevalence of metabolic syndrome ranged from 12.5-31.4 %, among which 5-7 % were young adults. Environmental factors, nutrition, and genetic and epigenetic predispositions are thought to interact intricately to cause metabolic disease. MicroRNAs are short, small non-coding RNAs that attach to the target coding sequences and untranslated genomic regions in many cell types, thereby post-transcriptionally suppressing gene expression. The human genome contains around 2000 microRNAs many of which appear linked to a numerous biologic and pathophysiologic processes, such as inflammatory response, angiogenesis, and glucose homeostasis. Many human disorders, including obesity, type 2 diabetes mellitus, and cardiovascular disorders, have been linked to deregulated microRNA expression. More recently, the identification of extracellular microRNAs has highlighted their potential as markers of disease and endocrine signaling molecules. This review provides an overview of microRNA biogenesis and its function in insulin signaling, adipogenesis, biology of pancreatic β-cell, and metabolism. We review current research on microRNAs linked to vascular diabetic complications and metabolic diseases, with a focus on their diagnostic and therapeutic potential.
{"title":"MicroRNAs in metabolic syndrome: Mechanisms, diagnosis, and therapy.","authors":"Md Abdur Rahman, Md Mahmodul Islam, Md Monirul Islam, Md Abdur Rahman Ripon, Mohammad Salim Hossain","doi":"10.1016/bs.acc.2025.06.003","DOIUrl":"10.1016/bs.acc.2025.06.003","url":null,"abstract":"<p><p>Metabolic syndrome is a group of cardio-metabolic dysfunctions characterized by increased fasting blood glucose, blood pressure, waist circumference, triglycerides, and decreased high-density lipoprotein cholesterol. Globally, the prevalence of metabolic syndrome ranged from 12.5-31.4 %, among which 5-7 % were young adults. Environmental factors, nutrition, and genetic and epigenetic predispositions are thought to interact intricately to cause metabolic disease. MicroRNAs are short, small non-coding RNAs that attach to the target coding sequences and untranslated genomic regions in many cell types, thereby post-transcriptionally suppressing gene expression. The human genome contains around 2000 microRNAs many of which appear linked to a numerous biologic and pathophysiologic processes, such as inflammatory response, angiogenesis, and glucose homeostasis. Many human disorders, including obesity, type 2 diabetes mellitus, and cardiovascular disorders, have been linked to deregulated microRNA expression. More recently, the identification of extracellular microRNAs has highlighted their potential as markers of disease and endocrine signaling molecules. This review provides an overview of microRNA biogenesis and its function in insulin signaling, adipogenesis, biology of pancreatic β-cell, and metabolism. We review current research on microRNAs linked to vascular diabetic complications and metabolic diseases, with a focus on their diagnostic and therapeutic potential.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"181-247"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heavy metal toxicity poses significant risks to environmental and human health, necessitating advanced analytical and integrative approaches for assessment and mitigation. Herein we review the use of high-resolution metabolomics, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS), and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) to identify metabolic disruptions associated with heavy metal exposure. NMR, due to a non-destructive nature and ability to provide quantitative and structural information, has emerged as a vital tool in identifying biomarkers and elucidating metabolic disruptions caused by heavy metals. Integrating genomics, transcriptomics, proteomics, and lipidomics with metabolomics has significantly enhanced the understanding of gene-environment interactions. Systems biology and computational modeling bridge experimental data with predictive insights, simulating complex interactions and identifying intervention points. Furthermore, this chapter explores advanced instrumentation and the role of interdisciplinary collaboration as metabolomics, enriched by NMR and multi-omics integration, holds the potential to manage the heavy metal toxicity, paving the way for precision medicine and environmental resilience.
{"title":"Metabolomics of heavy metal exposure.","authors":"Shagufta Kamal, Sumble Malik, Farwa Batool, Kanwal Rehman, Muhammad Sajid Hamid Akash","doi":"10.1016/bs.acc.2025.06.005","DOIUrl":"https://doi.org/10.1016/bs.acc.2025.06.005","url":null,"abstract":"<p><p>Heavy metal toxicity poses significant risks to environmental and human health, necessitating advanced analytical and integrative approaches for assessment and mitigation. Herein we review the use of high-resolution metabolomics, ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS), and Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS) to identify metabolic disruptions associated with heavy metal exposure. NMR, due to a non-destructive nature and ability to provide quantitative and structural information, has emerged as a vital tool in identifying biomarkers and elucidating metabolic disruptions caused by heavy metals. Integrating genomics, transcriptomics, proteomics, and lipidomics with metabolomics has significantly enhanced the understanding of gene-environment interactions. Systems biology and computational modeling bridge experimental data with predictive insights, simulating complex interactions and identifying intervention points. Furthermore, this chapter explores advanced instrumentation and the role of interdisciplinary collaboration as metabolomics, enriched by NMR and multi-omics integration, holds the potential to manage the heavy metal toxicity, paving the way for precision medicine and environmental resilience.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"128 ","pages":"109-154"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144985213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/S0065-2423(25)00090-3
Gregory S Makowski
{"title":"Preface.","authors":"Gregory S Makowski","doi":"10.1016/S0065-2423(25)00090-3","DOIUrl":"https://doi.org/10.1016/S0065-2423(25)00090-3","url":null,"abstract":"","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"129 ","pages":"xi-xii"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2024-11-22DOI: 10.1016/bs.acc.2024.11.002
Caio Ribeiro Vieira Leal, Heloisa Botezelli, Júlia Fernandes do Carmo Las Casas, Ana Cristina Simões E Silva, Fernando M Reis
Preeclampsia (PE), a pregnancy-related syndrome, has motivated extensive research to understand its pathophysiology and develop early diagnostic methods. 'Omic' technologies, focusing on genes, mRNA, proteins, and metabolites, have revolutionized biological system studies. Urine emerges as an ideal non-invasive specimen for omics analysis, offering accessibility, easy collection, and stability, making it valuable for identifying biomarkers. A comprehensive exploration of urinary omics in preeclampsia is discussed in this review. Proteomic studies identified biomarkers such as SERPINA-1 and uromodulin, showing promise for early diagnosis and severity assessment. Metabolomic analyses revealed alterations in metabolites like glycine and hippurate, providing insights into molecular mechanisms underlying PE. Challenges include methodological inconsistencies and the need for standardized protocols. Urinary omics technologies have significantly advanced our understanding of PE pathophysiology and hold promise for improved diagnosis and management. Biomarkers identified through these approaches offer potential for early detection, severity stratification, and elucidation of underlying mechanisms.
{"title":"Urinary biomarkers of preeclampsia: An update.","authors":"Caio Ribeiro Vieira Leal, Heloisa Botezelli, Júlia Fernandes do Carmo Las Casas, Ana Cristina Simões E Silva, Fernando M Reis","doi":"10.1016/bs.acc.2024.11.002","DOIUrl":"10.1016/bs.acc.2024.11.002","url":null,"abstract":"<p><p>Preeclampsia (PE), a pregnancy-related syndrome, has motivated extensive research to understand its pathophysiology and develop early diagnostic methods. 'Omic' technologies, focusing on genes, mRNA, proteins, and metabolites, have revolutionized biological system studies. Urine emerges as an ideal non-invasive specimen for omics analysis, offering accessibility, easy collection, and stability, making it valuable for identifying biomarkers. A comprehensive exploration of urinary omics in preeclampsia is discussed in this review. Proteomic studies identified biomarkers such as SERPINA-1 and uromodulin, showing promise for early diagnosis and severity assessment. Metabolomic analyses revealed alterations in metabolites like glycine and hippurate, providing insights into molecular mechanisms underlying PE. Challenges include methodological inconsistencies and the need for standardized protocols. Urinary omics technologies have significantly advanced our understanding of PE pathophysiology and hold promise for improved diagnosis and management. Biomarkers identified through these approaches offer potential for early detection, severity stratification, and elucidation of underlying mechanisms.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"124 ","pages":"197-211"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01Epub Date: 2025-01-30DOI: 10.1016/bs.acc.2024.11.007
Ulvi Kahraman Gürsoy, Ilias Oikonomou, Mustafa Yilmaz, Mervi Gürsoy
Periodontitis is the infectious-inflammatory disease of tooth-supporting tissues. Periodontal treatment, either non-surgical or surgical, aims to remove infection, reduce inflammation, eliminate tissue loss, and gain clinical attachment. Clinical and radiographic recordings are widely used and accepted as gold-standard methods in periodontal diagnostics. While these traditional methods allow clinicians to monitor and diagnose periodontitis, they cannot be used to estimate the course of periodontal healing, or predict the disease recurrence or estimate the treatment outcome. Early prediction of the long-term consequences of periodontal treatment would be a crucial and valuable information not only for the clinicians, but also for the patients. Rapid advancements during past few decades boosted the periodontal biomarker studies and various microbe- or host-derived biochemical markers have been suggested as diagnostic biomarkers of periodontitis. Yet, there is no consensus regarding the accuracy of diagnostic biomarkers to monitor treatment response or to predict prognosis. The aim of this chapter will be to describe the healing patterns of periodontal tissues after treatment and present the available evidence on biomarkers that can indicate or predict successful treatment outcomes.
{"title":"Advances in periodontal healing biomarkers.","authors":"Ulvi Kahraman Gürsoy, Ilias Oikonomou, Mustafa Yilmaz, Mervi Gürsoy","doi":"10.1016/bs.acc.2024.11.007","DOIUrl":"10.1016/bs.acc.2024.11.007","url":null,"abstract":"<p><p>Periodontitis is the infectious-inflammatory disease of tooth-supporting tissues. Periodontal treatment, either non-surgical or surgical, aims to remove infection, reduce inflammation, eliminate tissue loss, and gain clinical attachment. Clinical and radiographic recordings are widely used and accepted as gold-standard methods in periodontal diagnostics. While these traditional methods allow clinicians to monitor and diagnose periodontitis, they cannot be used to estimate the course of periodontal healing, or predict the disease recurrence or estimate the treatment outcome. Early prediction of the long-term consequences of periodontal treatment would be a crucial and valuable information not only for the clinicians, but also for the patients. Rapid advancements during past few decades boosted the periodontal biomarker studies and various microbe- or host-derived biochemical markers have been suggested as diagnostic biomarkers of periodontitis. Yet, there is no consensus regarding the accuracy of diagnostic biomarkers to monitor treatment response or to predict prognosis. The aim of this chapter will be to describe the healing patterns of periodontal tissues after treatment and present the available evidence on biomarkers that can indicate or predict successful treatment outcomes.</p>","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"125 ","pages":"143-167"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143485251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}